^
    Back
    Association details:
    Biomarker:EGFR expression + KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Tyrosine kinase inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO Open
    Title:

    KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

    Published date:
    10/01/2021
    Excerpt:
    The KRAS p.G12C mutation is detected in 1% of EGFR-positive NSCLC patients who progress on a first line with a TKI.
    DOI:
    https://doi.org/10.1016/j.esmoop.2021.100279